Literature DB >> 24276406

HPV typing of high-grade dysplasia (CIN III) in cone biopsies of 38 HPV-vaccinated women.

Ondrej Ondič1, Jana Kašpírková, Ondřej Májek, Iva Kinkorová.   

Abstract

HPV-vaccinated women develop CIN III very rarely. We have identified a study group of 38 such patients and showed that a specific HPV genotype prevalence in those cases equals the prevalence of HPV genotypes in CIN III present in the general Czech population. In all cases, CIN III was diagnosed within 3 years after having completed the HPV vaccination. We conclude that dysplasia was present before the vaccination in those women. A history of abnormal pre-vaccination PAP smear result (present in 78 % of women in the study group) and age of over 17 by the time of vaccination completion (97 % of women in the study group) are identified as probable factors increasing the risk of CIN III development after HPV vaccination.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24276406     DOI: 10.1007/s00428-013-1511-4

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  9 in total

1.  The incidence of HPV in a Swedish series of invasive cervical carcinoma.

Authors:  B Hagmar; B Johansson; M Kalantari; Z Petersson; B Skyldberg; L Walaas
Journal:  Med Oncol Tumor Pharmacother       Date:  1992

2.  [The testing strategy for detection of biologically relevant infection of human papillomavirus in head and neck tumors for routine pathological analysis].

Authors:  Jana Kašpírková; Ondrej Ondič; Kateřina Cerná; Alena Skálová
Journal:  Cesk Patol       Date:  2013-01

3.  Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in women aged 15-25 years with and without serological evidence of previous exposure to HPV-16/18.

Authors:  A Szarewski; W A J Poppe; S R Skinner; C M Wheeler; J Paavonen; P Naud; J Salmeron; S-N Chow; D Apter; H Kitchener; X Castellsagué; J C Teixeira; J Hedrick; U Jaisamrarn; G Limson; S Garland; B Romanowski; F Y Aoki; T F Schwarz; F X Bosch; D M Harper; K Hardt; T Zahaf; D Descamps; F Struyf; M Lehtinen; G Dubin
Journal:  Int J Cancer       Date:  2011-10-23       Impact factor: 7.396

4.  Detection of rare and possibly carcinogenic human papillomavirus genotypes as single infections in invasive cervical cancer.

Authors:  Daan Geraets; Laia Alemany; Nuria Guimera; Silvia de Sanjose; Maurits de Koning; Anco Molijn; David Jenkins; Xavier Bosch; Wim Quint
Journal:  J Pathol       Date:  2012-12       Impact factor: 7.996

Review 5.  An overview on the implementation of HPV vaccination in Europe.

Authors:  Paolo Bonanni; Miriam Levi; Nina B Latham; Angela Bechini; Emilia Tiscione; Piero Lai; Donatella Panatto; Roberto Gasparini; Sara Boccalini
Journal:  Hum Vaccin       Date:  2011-01-01

6.  A descriptive analysis of prevalent vs incident cervical intraepithelial neoplasia grade 3 following minor cytologic abnormalities.

Authors:  Philip E Castle; Patti E Gravitt; Nicolas Wentzensen; Mark Schiffman
Journal:  Am J Clin Pathol       Date:  2012-08       Impact factor: 2.493

Review 7.  Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936.

Authors:  J J M van Dongen; A W Langerak; M Brüggemann; P A S Evans; M Hummel; F L Lavender; E Delabesse; F Davi; E Schuuring; R García-Sanz; J H J M van Krieken; J Droese; D González; C Bastard; H E White; M Spaargaren; M González; A Parreira; J L Smith; G J Morgan; M Kneba; E A Macintyre
Journal:  Leukemia       Date:  2003-12       Impact factor: 11.528

8.  Human papillomavirus genotype distribution in Czech women and men with diseases etiologically linked to HPV.

Authors:  Ruth Tachezy; Jana Smahelova; Martina Salakova; Marc Arbyn; Lukas Rob; Petr Skapa; Tomas Jirasek; Eva Hamsikova
Journal:  PLoS One       Date:  2011-07-13       Impact factor: 3.240

9.  Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline.

Authors:  Mark Schiffman; Gary Clifford; Franco M Buonaguro
Journal:  Infect Agent Cancer       Date:  2009-06-01       Impact factor: 2.965

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.